Diabetics benefit less from clopidogrel than non-diabetics

In this administrative database analysis of patients post MI, clopiogrel was less effective in reducing all cause mortality and cardiovascular mortality in patients with diabetes compared to those without diabetes (abstract). Other anti-platelet agents (prasugrel and ticagrelor) may be more effective than clopidogrel among diabetics post MI.

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment